From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. Summary and Comment

High Mortality in a South African XDR TB Outbreak

Researchers found alarmingly high prevalences of both multidrug-resistant and extensively drug-resistant TB among HIV-coinfected people in rural South Africa.

This study was conducted in a rural subdistrict of KwaZulu-Natal, South Africa, where the local hospital has an established DOTS (Directly Observed Treatment, Short Course) program for TB treatment. In this hospital, 40% of inpatient beds are occupied by HIV-infected individuals.

From January 2005 through March 2006, sputum samples were collected for mycobacterial culture from 1539 patients. Cultures from 542 patients (35%) were positive for Mycobacterium tuberculosis. Multidrug-resistant (MDR) TB was identified in 221 of the culture-positive patients (41%), including 53 with extensively drug-resistant (XDR) TB (here defined as resistant to isoniazid, rifampin, ethambutol, streptomycin, aminoglycosides, and fluoroquinolones).

Genotyping studies, completed on isolates from 46 patients with XDR TB, revealed that 85% (95% confidence interval, 74%–95%) of patients with XDR TB were infected with a genetically similar strain, unique to KwaZulu-Natal. All 44 XDR TB patients with known HIV status were HIV-infected. Fifty-two of the 53 XDR TB patients died (median survival from the time of specimen collection, 16 days). Notably, 55% of the patients with XDR TB had never been treated for TB, and 30% had documented cure or completion of their previous TB treatment course.

Comment: To standardize the identification of XDR TB, CDC and WHO have jointly released a revised definition of XDR TB (MMWR 2006; 55:1176). The new definition stipulates resistance to isoniazid and rifampicin, as well as to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).

In the current study, which was presented at the 2006 XVI International AIDS Conference (see ACC Sep 18 2006), prevalences of MDR TB and XDR TB were substantially higher than those previously reported. (Only 347 cases of XDR TB were identified worldwide from 2000 though 2004.) Furthermore, XDR TB was rapidly — and almost uniformly — fatal. The convergence of the HIV and TB epidemics is placing great strain on healthcare services in resource-poor settings and threatens to overturn the survival gains achieved by DOTS for TB and by antiretroviral therapy for HIV infection. These findings highlight the importance of active surveillance for MDR and XDR TB, as well as the need for improved TB-treatment adherence, better diagnostic tools, and new therapeutic drugs.

— Salim S. Abdool Karim, MD, PhD

Published in AIDS Clinical Care November 13, 2006

Citation(s):

Gandhi NR et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006 Nov 4; 368:1575-80.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2006. Massachusetts Medical Society. All rights reserved.